Page last updated: 2024-11-04

ipodate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ipodate is a nonionic, water-soluble compound that contains iodine. It is used as a contrast agent in X-ray imaging of the gallbladder and biliary tree. It is thought to work by concentrating in the gallbladder and biliary tree, making these structures more visible on X-ray images. It has been used in the diagnosis of a variety of biliary disorders, including cholecystitis, cholelithiasis, and biliary duct obstruction. Ipodate is typically administered orally and is rapidly absorbed from the gastrointestinal tract. It is excreted primarily in the urine. While generally safe and well-tolerated, ipodate can cause adverse effects such as nausea, vomiting, diarrhea, and allergic reactions.'

Ipodate: Ionic monomeric contrast media. Usually the sodium or calcium salts are used for examination of the gall bladder and biliary tract. (From Martindale, The Extra Pharmacopoeia, 30th ed, p704) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5241
CHEMBL ID1201243
CHEMBL ID3306201
CHEBI ID81496
SCHEMBL ID37851
MeSH IDM0011700

Synonyms (46)

Synonym
5587-89-3
ipodic acid
3-(3-{[(1e)-(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoic acid
bilimin acid
2,4,6-triiodo-3-((dimethylaminomethylene)amino)hydrocinnamic acid
3-(3-dimethylaminomethyleneamino-2,4,6-triiodophenyl)propionic acid
beta-(3-(dimethylaminomethyleneamino)-2,4,6-triiodophenyl)propionic acid
iopodic acid
einecs 226-992-7
brn 2220636
bilopten
benzenepropanoic acid, 3-(((dimethylamino)methylene)amino)-2,4,6-triiodo-
ipodate
3-(((dimethylamino)methylene)amino)-3-(2,4,6-triiodophenyl)propionic acid
hydrocinnamic acid, 3-(((dimethylamino)methylene)amino)-2,4,6-triiodo-
hsdb 3347
oragrafin
3-[3-[(e)-dimethylaminomethyleneamino]-2,4,6-triiodo-phenyl]propanoic acid
STL069541
3-(3-{[(e)-(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoic acid
C18093
3-[3-(dimethylaminomethylideneamino)-2,4,6-triiodophenyl]propanoic acid
chebi:81496 ,
CHEMBL1201243
smr003500747
MLS004774078
AKOS005689228
f604zki910 ,
unii-f604zki910
iopodic acid [mart.]
iopodic acid [who-dd]
ipodate [vandf]
ipodate [mi]
ipodic acid [hsdb]
BBL023886
SCHEMBL37851
CHEMBL3306201
DTXSID0023167
DB09333
3-[[(dimethylamino)methylene]amino]-3-(2,4,6-triiodophenyl)propionic acid
3-(3-(((dimethylamino)methylene)amino)-2,4,6-triiodophenyl)propanoic acid
Q22294025
iopodic-acid
3-(3-(((dimethylamino)methylene)amino)-2,4,6-triiodophenyl)propanoicacid
3-(3-{[(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoic acid
EN300-25597632

Research Excerpts

Actions

ExcerptReferenceRelevance
"Ipodate appeared to inhibit in vivo metabolism of [125I]T3."( Roentgenographic contrast agents inhibit triiodothyronine binding to nuclear receptors in vitro.
DeGroot, LJ; Rue, PA, 1979
)
0.98

Treatment

ExcerptReferenceRelevance
"Ipodate treatment, on the other hand, resulted in a reduction of serum total T3 to 102 +/- 21 ng/dl, an increase in total T4 to 9.59 +/- 0.50 micrograms/dl, free T4 to 1.91 +/- 0.13 ng/dl and TSH to 3.64 +/- 1.14 microU/ml."( Blunted peripheral tissue responsiveness to thyroid hormone in uremic patients.
Flanigan, MJ; Freeman, RM; Lim, VS; Zavala, DC, 1987
)
0.99

Dosage Studied

ExcerptRelevanceReference
"Cholecystography was carried out on 456 consecutive patients using varying dosage schedules of cholebrine (iocetamic acid) tablets and biloptin (sodium iopodate) tablets."( A comparison of iocetamic acid and sodium iopodate in cholecystography.
Golberg, B, 1977
)
0.26
" Rat liver and kidney microsomes produced dose-response curves that were essentially parallel to that of LAP-744."( A radioimmunoassay of rat type I iodothyronine 5'-monodeiodinase.
Chopra, IJ; Santini, F, 1992
)
0.28
" Its advantages over conventional therapy are a rapid fall in thyroid hormones and control of symptoms with a simple dosage regime."( Resistant hyperthyroidism induced by sodium iopodate used as treatment for Graves' disease.
Caldwell, G; Errington, M; Toft, AD, 1989
)
0.28
" Dosage of ipodate was increased to 150 mg/d and then to 200 mg/d at 2-week intervals if a good clinical response was not observed."( Ipodate treatment of hyperthyroidism in cats.
Murray, LA; Peterson, ME, 1997
)
2.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency32.19680.007215.758889.3584AID624030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.00000.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (179)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990159 (88.83)18.7374
1990's15 (8.38)18.2507
2000's3 (1.68)29.6817
2010's2 (1.12)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.73 (24.57)
Research Supply Index5.36 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index72.10 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (9.28%)5.53%
Reviews6 (3.09%)6.00%
Case Studies8 (4.12%)4.05%
Observational0 (0.00%)0.25%
Other162 (83.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]